Xu Zhen, Zhou Xin, Peng Bo, Rao Yanxia
Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Department of Neurosurgery, Huashan Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China.
STAR Protoc. 2021 Jul 7;2(3):100666. doi: 10.1016/j.xpro.2021.100666. eCollection 2021 Sep 17.
Microglia are important immune cells in the central nervous system (CNS). Mutations in microglia may cause CNS disorders. Replacement of dysfunctional microglia with allogeneic wild-type microglia can correct the gene deficiency, thus treating the neurogenic diseases. However, traditional approaches cannot efficiently replace microglia at the adulthood. Here, we introduce a potentially clinical-feasible strategy named microglia replacement by bone marrow transplantation that achieves efficient microglia replacement at the whole CNS scale, including the brain, spinal cord, and retina in adult mice. For complete details on the use and execution of this protocol, please refer to Xu et al. (2020). The original abbreviation of this microglia replacement strategy is mrBMT. We hereby change the name to Mr BMT.
小胶质细胞是中枢神经系统（CNS）中的重要免疫细胞。小胶质细胞的突变可能导致中枢神经系统疾病。用同种异体野生型小胶质细胞替代功能失调的小胶质细胞可以纠正基因缺陷，从而治疗神经源性疾病。然而，传统方法在成年期无法有效地替代小胶质细胞。在此，我们介绍一种具有潜在临床可行性的策略，即通过骨髓移植进行小胶质细胞替代，该策略可在成年小鼠的整个中枢神经系统范围内，包括脑、脊髓和视网膜，实现高效的小胶质细胞替代。有关本方案的使用和实施的完整详细信息，请参考Xu等人（2020年）的研究。这种小胶质细胞替代策略的原始缩写是mrBMT。我们在此将其名称更改为Mr BMT。
